Subtopic Deep Dive
Neuroprotective Effects of Sigma-1 Agonists
Research Guide
What is Neuroprotective Effects of Sigma-1 Agonists?
Neuroprotective effects of sigma-1 agonists refer to the cell survival promotion by sigma-1 receptor activation in preclinical models of stroke, ALS, Alzheimer's, and Parkinson's via mechanisms including BDNF signaling and autophagy.
Sigma-1 receptors at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival (Hayashi and Su, 2007, 1738 citations). Agonists like PRE-084 and donepezil show neuroprotection in amyloid β models and experimental stroke (Meunier et al., 2006, 280 citations; Ruscher et al., 2011, 167 citations). Over 10 key papers from 1995-2019 document these effects across 168-1738 citations.
Why It Matters
Sigma-1 agonists restore motor function and motoneuron survival in ALS mice (Mancuso et al., 2012). They enhance brain plasticity and recovery post-stroke via sigma-1 activation (Ruscher et al., 2011). Donepezil's neuroprotection against amyloid β25-35 involves sigma-1 interaction, supporting repurposing for Alzheimer's (Meunier et al., 2006). Pharmacological stimulation yields neurorestorative effects in parkinsonism models (Francardo et al., 2014). These findings position sigma-1 agonists as candidates for untreatable neurodegenerative diseases.
Key Research Challenges
Translating Preclinical Neuroprotection
Preclinical models show sigma-1 agonist benefits in stroke and ALS, but human trials lack (Ryskamp et al., 2019). Species differences in sigma-1 distribution hinder extrapolation. Over 195 papers cite ER-mitochondria mechanisms without clinical validation (Hayashi and Su, 2007).
Sigma-1 Ligand Selectivity
Distinguishing sigma-1 from sigma-2 effects remains unresolved despite pharmacological profiles (Cobos et al., 2008, 367 citations). Cytotoxic effects occur at high ligand doses in glioma cells (Vil'ner et al., 1995). Agonist specificity challenges therapeutic dosing.
Mechanism Elucidation in Disease Models
BDNF and autophagy roles in sigma-1 neuroprotection need precise mapping across Alzheimer's and Parkinson's (Maurice and Su, 2009). Steroid interactions add non-genomic complexity (Monnet and Maurice, 2006). Integrating Ca2+ signaling data gaps persist (Hayashi and Su, 2007).
Essential Papers
Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival
Teruo Hayashi, Tsung‐Ping Su · 2007 · Cell · 1.7K citations
The pharmacology of sigma-1 receptors
Tangui Maurice, Tsung‐Ping Su · 2009 · Pharmacology & Therapeutics · 625 citations
Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Enrique J. Cobos, José Manuel Entrena, Francisco R. Nieto et al. · 2008 · Current Neuropharmacology · 367 citations
Sigma (sigma) receptors, initially described as a subtype of opioid receptors, are now considered unique receptors. Pharmacological studies have distinguished two types of sigma receptors, termed s...
The anti‐amnesic and neuroprotective effects of donepezil against amyloid β<sub>25‐35</sub>peptide‐induced toxicity in mice involve an interaction with the<i>σ</i><sub>1</sub>receptor
Johann Meunier, John R. Ieni, Tangui Maurice · 2006 · British Journal of Pharmacology · 280 citations
Background and purpose: The acetylcholinesterase inhibitor, donepezil, is also a high affinity σ 1 receptor agonist. We examined the involvement of σ 1 receptors in its anti‐amnesic and neuroprotec...
Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases
Daniel A. Ryskamp, Svetlana A. Korban, Vladimir Zhemkov et al. · 2019 · Frontiers in Neuroscience · 195 citations
Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with variou...
Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism
Veronica Francardo, Francesco Bez, Tadeusz Wieloch et al. · 2014 · Brain · 195 citations
The sigma-1 receptor, an endoplasmic reticulum-associated molecular chaperone, is attracting great interest as a potential target for neuroprotective treatments. We provide the first evidence that ...
Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability
B. Ya. Vil'ner, BR de Costa, WD Bowen · 1995 · Journal of Neuroscience · 168 citations
The morphological effects of several neuroleptics as well as other novel and prototypic sigma ligands were examined by addition to cultures of C6 glioma cells. Sigma ligands caused loss of processe...
Reading Guide
Foundational Papers
Start with Hayashi and Su (2007, 1738 citations) for core ER-mitochondria Ca2+ mechanisms, then Maurice and Su (2009, 625 citations) for pharmacology, followed by Meunier et al. (2006, 280 citations) for amyloid model evidence.
Recent Advances
Study Ryskamp et al. (2019, 195 citations) for signaling in neurodegeneration; Mancuso et al. (2012, 162 citations) for ALS motoneuron survival.
Core Methods
Agonist administration in ALS mice, stroke-enriched housing paradigms, amyloid β25-35 toxicity assays, and morphological viability in glioma cultures (Mancuso et al., 2012; Ruscher et al., 2011; Vil'ner et al., 1995).
How PapersFlow Helps You Research Neuroprotective Effects of Sigma-1 Agonists
Discover & Search
Research Agent uses searchPapers and exaSearch to find sigma-1 neuroprotection papers like 'Sigma-1R Agonist Improves Motor Function and Motoneuron Survival in ALS Mice' (Mancuso et al., 2012), then citationGraph maps influences from Hayashi and Su (2007, 1738 citations) to reveal stroke and ALS clusters, while findSimilarPapers uncovers related PRE-084 studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract Ca2+ signaling mechanisms from Hayashi and Su (2007), verifies claims with verifyResponse (CoVe) against Maurice and Su (2009), and runs PythonAnalysis on dose-response data from Meunier et al. (2006) for statistical verification of donepezil's sigma-1 effects, with GRADE grading for evidence strength in neuroprotection models.
Synthesize & Write
Synthesis Agent detects gaps in clinical translation from preclinical ALS data (Mancuso et al., 2012), flags contradictions between cytotoxic (Vil'ner et al., 1995) and protective effects, while Writing Agent uses latexEditText, latexSyncCitations for Ruscher et al. (2011), and latexCompile to generate review manuscripts with exportMermaid diagrams of ER-mitochondria pathways.
Use Cases
"Analyze dose-response curves of sigma-1 agonists in ALS mouse models from Mancuso 2012."
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas curve fitting, matplotlib plots) → statistical outputs with p-values and IC50 estimates.
"Draft LaTeX review on sigma-1 agonists in stroke recovery citing Ruscher 2011."
Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (add Ruscher et al.) → latexCompile → PDF with compiled figures.
"Find GitHub code for sigma-1 receptor simulations linked to Hayashi 2007."
Research Agent → paperExtractUrls (Hayashi Su 2007) → paperFindGithubRepo → githubRepoInspect → code snippets for Ca2+ modeling in Python sandbox.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ sigma-1 papers: searchPapers → citationGraph → DeepScan (7-step analysis with CoVe checkpoints on neuroprotection claims). Theorizer generates hypotheses on BDNF-autophagy links from Mancuso (2012) and Ryskamp (2019), chaining readPaperContent → runPythonAnalysis → theory export. DeepScan verifies PRE-084 efficacy across stroke models (Ruscher 2011).
Frequently Asked Questions
What defines neuroprotective effects of sigma-1 agonists?
Sigma-1 agonists promote cell survival in stroke, ALS, and Alzheimer's models via ER-mitochondria Ca2+ regulation and BDNF (Hayashi and Su, 2007; Mancuso et al., 2012).
What are key methods for studying sigma-1 neuroprotection?
Mouse models of amyloid β toxicity, experimental stroke, and ALS test agonists like donepezil and PRE-084, measuring motoneuron survival and functional recovery (Meunier et al., 2006; Ruscher et al., 2011).
What are foundational papers?
Hayashi and Su (2007, 1738 citations) on ER-mitochondria chaperoning; Maurice and Su (2009, 625 citations) on pharmacology; Meunier et al. (2006, 280 citations) on donepezil's sigma-1 effects.
What open problems exist?
Clinical translation from preclinical models, sigma-1 vs sigma-2 selectivity, and precise BDNF-autophagy mechanisms in humans remain unresolved (Ryskamp et al., 2019; Cobos et al., 2008).
Research Pharmacological Receptor Mechanisms and Effects with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neuroprotective Effects of Sigma-1 Agonists with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers